Ki-67 (MRQ-64) Rabbit Monoclonal Antibody
Specialties: Anatomic Pathology Breast/Gynecological Pathology
Ki-67 (MRQ-64) is an antibody designed to target Ki-67 antigen-a nuclear protein encoded by the MKI67 gene whose presence correlates with G1, S, G2, and the mitotic phases of the cell cycle.1 Though its specific role is largely postulated and still yet to be determined, Ki-67’s presence during cellular division makes it an excellent target for labeling rapidly growing malignancies.2 Given that its presence correlates with cell proliferation, the immunohistochemical labeling of Ki-67 antigen may be useful in characterizing a lesion’s growth fraction. It has been demonstrated that identifying this antigen by IHC is useful in characterizing lesions of the breast, lymphoid cells, astrocytes, and uterus.3-9
- Scholzen T, et al. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000; 182(3):311-22.
- Sun X, et al. Ki-67: more than a proliferation marker. Chromosoma. 2018; 127(2):175-186.
- Abd-Elazeem MA, et al. Claudin 4 expression in triple-negative breast cancer: correlation with androgen receptors and Ki-67 expression. Annals of Diagnostic Pathology 2015; 19:37-42.
- Inwald EC, et al. Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry. Breast Cancer Res Treat. 2013; 139(2):539-552.
- Ning J, et al. The impact of Ki-67 in the context of multidisciplinary care in primary inflammatory breast cancer. J Cancer. 2019; 10(12):2635-2642.
- Broyde A, et al. Role and prognostic significance of the Ki-67 index in non-Hodgkin's lymphoma. Am J Hematol. 2009; 84(6):338-43.
- Chuang SS, et al. Histopathology and immunohistochemistry in distinguishing Burkitt lymphoma from diffuse large B-cell lymphoma with very high proliferation index and with or without a starry-sky pattern: a comparative study with EBER and FISH. Am J Clin Path 2007 128(4):558-64.
- Shivaprasad NV, et al. Ki-67 immunostaining in astrocytomas: Association with histopathological grade- A South Indian Study. J Neurosci Rural Pract. 2016 7(4):510-514.
- Mayerhofer K, et al. Ki-67 expression in patients with uterine leiomyomas, uterine smooth muscle tumors of uncertain malignant potential (STUMP) and uterine leiomyosarcomas (LMS). Acta Obstet Gynecol Scand. 2004; 83(11):1085-8.
Specifications
- Reactivity: paraffin
- Control: Tonsil (Nuclear); Breast duct carcinoma in situ (Nuclear); Burkitt lymphoma (Nuclear)
- Dilution Range: 1:25-1:100 *
Package Inserts
IFU
- IVD Rev. 0.0 (CMC27533000)
Have a different keycode?
Click Here
Learn how to obtain your SDS
Ordering Information
For in vitro diagnostic (IVD) use in USA
| 25.0 mL predilute ready-to-use | 275R-30 |
| 0.1 mL concentrate | 275R-34 |
| 0.5 mL concentrate | 275R-35 |
| 1.0 mL concentrate | 275R-36 |
| 1.0 mL predilute ready-to-use | 275R-37 |
| 7.0 mL predilute ready-to-use | 275R-38 |
For research use only (RUO) in Canada
| 25.0 mL predilute ready-to-use (RUO) | 275R-30-RUO |
| 0.1 mL concentrate (RUO) | 275R-34-RUO |
| 1.0 mL concentrate (RUO) | 275R-36-RUO |
| 1.0 mL predilute ready-to-use (RUO) | 275R-37-RUO |
| 7.0 mL predilute ready-to-use (RUO) | 275R-38-RUO |
For in vitro diagnostic (IVD) use in Europe
| 25.0 mL predilute ready-to-use | 275R-30 |
| 0.1 mL concentrate | 275R-34 |
| 0.5 mL concentrate | 275R-35 |
| 1.0 mL concentrate | 275R-36 |
| 1.0 mL predilute ready-to-use | 275R-37 |
| 7.0 mL predilute ready-to-use | 275R-38 |
For research use only (RUO) in Japan
| 25.0 mL predilute ready-to-use (RUO) | 275R-30-RUO |
| 0.1 mL concentrate (RUO) | 275R-34-RUO |
| 1.0 mL concentrate (RUO) | 275R-36-RUO |
| 1.0 mL predilute ready-to-use (RUO) | 275R-37-RUO |
| 7.0 mL predilute ready-to-use (RUO) | 275R-38-RUO |
To request information on this product in additional countries, please click the button below.
